Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCY real-world study of olaparib in HER2-negative metastatic breast cancer
2017-001054-34Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of olaparib in breast cancer, sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Sep 2017; status: completed.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2017-001054-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001054-34.